A Prospective, Randomized, Non-Inferiority Trial to Determine the Safety and Efficacy of the BA9TM Drug Coated Balloon for the Treatment of In-Stent Restenosis: First-in-Man Trial (REFORM)
Latest Information Update: 16 Aug 2022
At a glance
- Drugs Umirolimus (Primary) ; Paclitaxel
- Indications Coronary artery restenosis
- Focus First in man; Therapeutic Use
- Acronyms REFORM
- Sponsors Biosensors Europe
Most Recent Events
- 09 Aug 2022 Planned End Date changed from 1 Apr 2023 to 1 Apr 2024.
- 09 Aug 2022 Planned primary completion date changed from 1 Oct 2021 to 1 Apr 2023.
- 09 Aug 2022 Status changed from recruiting to active, no longer recruiting.